VSING (08292) announced its interim results, reporting a loss attributable to shareholders of 4.037 million ringgit, an increase of 52.97% year-on-year.

20:35 27/08/2026

VSING (08292) reported its results for the six months ended June 30, 2026, during which the group recorded revenue of 54.141 million ringgit, a year-on-year decrease of 3.02%; the loss attributable to shareholders was 4.037 million ringgit, an increase of 52.97% year-on-year; basic loss per share was 0.37 sen.

VSING (08292) announced its performance for the six months ending June 30, 2026. During this period, the group recorded revenue of 54.141 million Malaysian Ringgit, a decrease of 3.02% year-on-year; the loss attributable to shareholders was 4.037 million Malaysian Ringgit, an increase of 52.97% year-on-year; basic loss per share was 0.37 sen.

MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.

AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.

MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.

AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.

IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.